Nitric oxide (NO) is a gaseous neurotransmitter thought to play important roles in several behavioral domains. On a neurobiological level, NO acts as the second messenger of the Nmethyl-D-aspartate receptor and interacts with both the dopaminergic as well as the serotonergic system. Thus, NO is a promising candidate molecule in the pathogenesis of endogenous psychoses and a potential target in their treatment. Furthermore, the chromosomal locus of the gene for the NO-producing enzyme NOS-I, 12q24.2, represents a major linkage hot spot for schizophrenic and bipolar disorder. To investigate whether the gene encoding NOS-I (NOS1) conveys to the genetic risk for those diseases, five NOS1 polymorphisms as well as a NOS1 mini-haplotype, consisting of two functional polymorphisms located in the transcriptional control region of NOS1, were examined in 195 chronic schizophrenic, 72 bipolar-I patients and 286 controls. Single-marker association analysis showed that the exon 1c promoter polymorphism was linked to schizophrenia (SCZ), whereas synonymous coding region polymorphisms were not associated with disease. Long promoter alleles of the repeat polymorphism were associated with less severe psychopathology. Analysis of the mini-haplotype also revealed a significant association with SCZ. Mutational screening did not detect novel exonic polymorphisms in patients, suggesting that regulatory rather than coding variants convey the genetic risk on psychosis. Finally, promoter polymorphisms impacted on prefrontal functioning as assessed by neuropsychological testing and electrophysiological parameters elicited by a Go-Nogo paradigm in 48 patients (continuous performance test). Collectively these findings suggest that regulatory polymorphisms of NOS1 contribute to the genetic risk for SCZ, and modulate prefrontal brain functioning.
Introduction
Schizophrenia (SCZ), one of the most devastating mental illnesses, has a substantial genetic background with a heritability of up to 81%; 1 however, only risk genes contributing with small odds ratios were replicated in association studies. Furthermore, > 20 linkage analyses were conducted to date, including > 1200 pedigrees with almost 3000 affected cases.
Replicated loci include 1q, 6p24, 8p21, 13q32 and 22q11 and led to positional cloning approaches resulting in haplotype analyses of candidate genes. Among the most intensively studied, RGS4, dysbindin, neuregulin-1 and G72/G30 were replicated, 2 although at-risk haplotypes showed substantial discrepancies between populations and only consisted of probably non-functional, mostly intronic polymorphisms. Thus, no functional gene variant or mutations were yet derived from linkage analyses. Apparently the same is true for bipolar disorder (BPD), which shows considerable overlap with SCZ with regards to risk loci (13q, 22q). 3, 4 A further consistently identified locus for endogenous psychoses, usually with Lod scores between 2 and 3, is located on 12q22-24. BPD has been replicated 8 times, [5] [6] [7] [8] [9] [10] [11] [12] but also major depression (MD) was linked to this locus with a very high Lod-score > 6, which might be due to the homogeneity of the sample consisting of 110 pedigrees from Utah. 13 SCZ and schizoaffective disorder [14] [15] [16] [17] and the marker 'negative symptoms' in SCZ 18 linked to 12q22-24 as well. Furthermore, Darier's disease, a dermatological disorder mapping to 12q24.2, co-segregates with BPD. [19] [20] [21] [22] Finally, obesity as a side-effect of neuroleptics maps to this region. 23 Figure 1 provides an overview on linkage findings on 12q22-24 reported to date.
One intriguing candidate gene on 12q24 is the socalled neuronal isoform of nitric oxide synthase, NOS-I. NOS-I is the main source of NO in excitable tissue and can be found in up to 1% of all neurons. 24 NO is a pleiotropic messenger molecule, which inter alia functions as the second messenger of the Nmethyl-D-aspartate (NMDA) receptor. 25 Furthermore, the nitrinergic system is not only closely connected to the dopamine system, but also to serotonergic neurotransmission which provides a rationale for the involvement of NO and its pathway in both schizophrenic and affective disorders. Accordingly, a rapidly increasing body of evidence coming from pharmacological studies in animals argues in favour of this hypothesis. [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] Finally, a landmark study by Akbarian et al., 36, 37 followed by further histopathological investigations, 38 argues that nitrinergic neurons are pathologically altered in SCZ.
Interestingly, a single but not precisely described marker within NOS1 (the gene encoding NOS-I) reached a P < 0.05 for association with BPD. 10 D12S366, located only 800 kb from NOS1, was found to be associated with BPD and SCZ in three studies. 14, 15, 39 The human NOS1 gene is of outstanding complexity and features 12 alternative untranslated first exons, termed exon 1a-1l, driven by distinct promoters. The genomic region covering these alternative promoter-exons units spans 130 kilobases; the coding regions, consisting of 28 exons, extend over further 110 kilobases. Four association studies were published investigating a synonymous, exonic single nucleotide polymorphism (SNP) in exon 29 (which codes for the last 4 amino acids of the translated protein and the 3 0 -UTR), or an SNP in intron 29 of NOS1 in SCZ and depression. The first study, including 200 patients, reported an association of NOS1 with SCZ, 40 while a replication study including 200 subjects was negative. 41 Another association study aiming at BPD failed to detect association as well, 42 as did another report on MD. 43 In summarizing these conflicting findings, it needs to be emphasized that all studies investigated only one SNP, which by itself most likely is not functional, so that the power to detect modest gene effects is probably insufficient. Intriguingly, also proteins that interact with NOS-I were suggested to play a role in SCZ. Linkage of the disease to carboxy-terminal PDZ ligand of neuronal NO synthase (CAPON) on chromosome 1q22 was demonstrated in two independent studies: 44, 45 CAPON is an adaptor protein, regulating the coupling of NOS-I to the NMDA receptor via the enzyme's PSD95 domain. PSD95 expression in turn is decreased in SCZ and BPD. 46 Based on genetic and functional findings, NOS1 thus represents a candidate gene of considerable interest. Since studies conducted to date are ambiguous, we chose to perform a haplotype analysis of NOS1 including four SNPs, one of which is a functional promoter variant, and one promoter variable number of tandem repeat (VNTR) in SCZ and BPD. We hypothesized that promoter variants with functional impact, but not synonymous exonic SNPs are associated with disease. To screen for novel coding region variants, we also conducted a mutational analysis of protein coding exons. Finally, the variants of NOS1's transcriptional control region thought to influence gene expression were investigated concerning their neurophysiological and neuropsychological impact.
Materials and methods

Subjects
A total of 267 unrelated patients (mean age 44714 years; 125 male, 148 female) from the Lower Franconia area in Germany participated in this study, which were ascertained at the Department of Psychiatry and Psychotherapy, University of Wü rzburg. All patients were inpatients at the Department of Psychiatry at least once. One hundred and ninety-five patients suffered from schizophrenic disorders according to ICD-10 criteria (56, Figure 1 Based on the chromosomal location built on Ensembl Freeze 04/04, Lod scores of markers on 12q24 are given; the investigated phenotype was either SCZ, [14] [15] [16] [17] [18] 23 bipolar disorder [5] [6] [7] [8] [9] [10] [11] [12] 19, 22 or major depression. 13 Highlighted are the loci for DAAO, suggested as a candidate gene for bipolar disorder and SCZ, ATP2A2 (the Darier's disease gene) and NOS1.
remitted completely during the course of the disease and thus the sample consists entirely of patients suffering from chronic SCZ, that is, it is selected for severe cases. To test whether different classification systems lead to more refined results, the Leonhard classification 47 was additionally applied and patients were subdivided into two subgroups, the first comprising of highly heritable schizophrenic disorders with bipolar course (group A SCZ; n = 147; so-called 'unsystematic SCZ') and the second covering less heritable disorders leading to stable residual states (group B SCZ; n = 48; 'systematic SCZ'). Brief Psychiatric Rating Scale (BPRS) ratings were performed by an experienced rater (AR) in 119 patients. The mean Global Assessment of Functioning (GAF) score of those patients was 52710, mean BPRS score was 4079. This relatively low BPRS score is explained by the fact that all patients consented after the beginning of neuroleptic treatment and according clinical improvement.
Seventy-two inpatients suffered from BPD according to ICD-10 criteria. Only patients with at least one manic and one depressive episode leading to treatment were classified as BPD (i.e., strict bipolar-I criteria). While 82 SCZ spectrum disorder subjects had a positive family history for psychosis in firstdegree relatives (corresponding to 42% of the total sample; in systematic SCZ 9/48 patients had a positive family history, in unsystematic SCZ 73/147; w 2 = 17.04, P < 0.0001), 66 BPD patients ( = 91%) had a positive family history, in almost all cases for depression or BPD.
None of the subjects showed significant neurological comorbidity, epilepsy, mental retardation or other somatic disorders suggesting organic psychiatric disorder. Patients with substance-induced psychotic or affective episodes were excluded from the study as well. Diagnoses were made by an extensive, semistructured interview analogous to the AMDP interview 48 performed by an experienced psychiatrist (AR or CPJ), along with chart reviews. If possible, further information was retrieved from family informants and case records from other hospitals to ensure consistent diagnoses. Chart reviews of every patient were performed by AR.
A sample of DNA probes derived from 284 control subjects (150 males, 134 females) has been collected, consisting of healthy blood donors stemming from the same catchment area as the patient group. The sample was not screened for psychiatric disorders; however, all subjects were free of medication, and the study was explained to them, so that the likelihood that severe psychiatric disorders, especially chronic SCZ, present in the control sample was low. Mean age of controls was 35713 years. Both patients as well as controls were of Caucasian origin. Only patients and volunteers who gave written informed consent after oral as well as written explanation about scope and aim of the investigation were enrolled in the study. The study was approved by the Ethics Committee of the University of Wü rzburg.
Genomic control
To control for ethnic stratification, five highly polymorphic short tandem repeat (STR) markers (D2S2186, D3S1314, D4S2950, D22S420 and NOS1 VNTR1) were determined by PCR amplification and size determination was as described below. STR repeat frequencies can be obtained from the corresponding author on request. Thereafter, the CLUMP, 49 CHECKHET, 50 GENEPOP, 51 POWERMARKER 52 and STRUCTURE 53 software packages were used to investigate for population stratification both between as well as within the patient and the control sample.
Genotyping
For haplotype analysis, four SNPs and one VNTR 54 were chosen as markers. (Nomenclature with regards to NOS1 exon structure varies across different publications, as multiple exons 1 exist, which are not translated, so that exon 2 represents the first translated exon. Therefore, this exon sometimes is designated as exon 1. In this paper, exon 1 refers to the alternatively spliced UTR exons (in detail termed exon 1a-1l), exon 2 is the first and exon 29 the last translated exon.) Both the VNTR (hereafter termed VNTR1) and one SNP (G-84A; hereafter termed SNP1; Saur et al.
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) are within the promoter region of NOS1 exons 1f (VNTR1) and 1c (SNP1), respectively, and were suggested to be functional. Three further SNPs were selected, which are located within the exons 13 (rs2293054, SNP2), 18 (rs1047735; SNP3) and 29 (rs2133681; SNP4). Another SNP (SNP5), originally intended to be included in subsequent analysis (located in exon 27; rs2293044), was not used following genotyping, as only one patient and four controls were heterozygous for this polymorphism, contrary to database information giving a heterozygosity index of 0.162. All exonic SNPs are synonymous.
VNTR1 has been determined by PCR amplification and product size determination. One of the primers, VNTR1-Fw, was labeled with a fluorescent dye (cy-5; TIB MolBiol, Berlin) enabling detection of the resulting PCR product. PCR was performed in a 50-ml reaction mix containing 50 nM primers, 200 mM dNTPs, 1.5 mM MgCl 2 in PCR-buffer, 50 ng template DNA, and 0.4 U Taq polymerase. Initial denaturation for 3 min at 961C was followed by 33 cycles of 961C for 20 s, 581C for 20 s and 721C for 30 s. Electrophoretic separation of the PCR products was performed using a CEQ8000 DNA-sequencer (Beckman-Coulter, Krefeld, Germany). An external standard allows size determination of the PCR products. Internal standards contain previously sequenced DNA fragments of known alleles. VNTR1 genotyping was accomplished by comparing the allele sizes in each sample with the sizes of known alleles. The STR markers D2S2186, D3S1314, D4S2950, D22S420 were genotyped analogously except that touchdown PCR was performed using all four primer pairs in one reaction. Cy 5 and cy 5.5 fluorescent primers were used (TIB MolBiol, Berlin). After initial denaturation for 3 min at 961C, 10 cycles of 20 s denaturation at 961C, annealing for 20 s at decreasing temperatures of 63-531C and elongation for 30 s at 721C were followed by 30 cycles as above with 531C annealing temperature. SNP2 (IVS13 þ 13 C-G) was determined by denaturing high performance liquid chromatography (dHPLC) analysis following routine PCR. Heteroduplexes were obtained by denaturating for 2 min at 961C and cooling down to 41C at 21C s
À1
. Genotype analysis was performed on a Transgenomic WAVE system using the DNASept column (Transgenomic, Elancourt, France). Melting characteristics and separation method of the DNA fragment were predicted by use of the wavemakert software (version 4.1.44). Five microliters of the PCR product were injected and separated at 631C. Heteroduplexes appeared in two separated peaks in the chromatogram and could reliably be differentiated from homozygotes showing only one DNA peak. Samples shown by dHPLC analysis to contain one uniform sequence were mixed with equal amounts of a wild-type PCR product (typically 10 ml of each), denatured and re-annealed; 5 ml of this mixture were separated on the WAVE system. SNP1, SNP3 and SNP4 were genotyped by standard PCR and subsequent digest with Fnu4HI (SNP1), NlaIII (SNP3) and Eco72I (SNP4) followed by gel electrophoresis. Primer pairs for all polymorphisms and detailed PCR conditions are available on request.
Mutational analysis
In 205 patients (160, SCZ spectrum disorders; 45, BPDs) of the above sample, coding regions critical for the function of NOS-I (exon 2, containing the PSD-95 and PIN binding domains; exons 5 and 6, containing the heme binding domain; exon 13 and 14, containing the CaM binding site; and exon 27, contributing to the NADPH binding site) were screened for mutations. To do so, exons were amplified by PCR and sequenced. For preparing the amplicons, the PCR Product PreSequencing Kit was used according to the instructions given by the supplier (USB, Cleveland, OH, USA). The subsequent products were subjected to cycle sequencing using the Quick Start Sequencing Kit (Beckman, Krefeld, Germany). In brief, each sequencing reaction contained 2 ml purified PCR product, 2 ml reaction mix and 5 pmol primer in a 10 ml reaction. Cycle sequencing and subsequent ethanol precipitation was performed according to the manufacturer's instructions. The sequencing products were electrophoresed in a CEQ8000 DNAsequencer (Beckman, Krefeld, Germany). The remaining exons were screened by the same method in 20 selected patients (16, SCZ spectrum disorders; four, bipolar affective disorders). Primer sequences are available on request.
Statistical and haplotype analysis
Single association tests were performed by means of w 2 tests using SPSS for Windows 9.0. (SPSS Inc., Chicago, IL, USA). Pairwise linkage disequilibrium (LD) between the polymorphisms was assessed using 2LD. 56 Tests for global haplotype associations and for significance of differences between controls and patients in estimated frequencies of specific haplotypes were performed using the GENECOUNTING/ PERMUTE utility of the GENECOUNTING software. 56 Both programs are available for download at: http://web1.iop.kcl.ac.uk/iop/Departments/PsychMed/ GEpiBSt/software.shtml. GENECOUNTING implements an expectation maximization algorithm to resolve uncertain haplotypes and provides maximum-likelihood estimates of haplotype frequencies. It performs permutation tests for global association/significance of specific haplotypes by randomly reassigning case and control labels in the actual data. The resulting P-values reflect the proportion of replicates that produce values of statistics at least as large as the observed. In the current study, 10 000 permutations were performed.
Semiquantitative real-time PCR of NOS1 exon 1c and 1f in human brain Post-mortem adult human brain specimens of two autopsy cases were obtained from the Austro-German brain bank (Wü rzburg, Germany; Gsell et al.
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). Individuals had neither a history of neurological nor of psychiatric disorders and lacked any neuropathological abnormalities. The following regions were obtained: cortex frontalis, cortex frontoorbitalis, caput nuclei caudate, corpus nuclei caudate, putamen pars posterior and hippocampus. Dissection protocols and sample preparations were described previously. 57 Total RNA was isolated using the RNeasy RNA isolation kit (Qiagen, Hilden, Germany) and the RNase-free DNase Set (Qiagen) following the manufacturer's protocols. Five hundred nanograms of total RNA were reverse transcribed using the iScriptt cDNA Synthesis Kit (BioRad, Cambridge, MA, USA). Thereafter, expression of human NOS1 mRNA variants was quantified as described before 55 using an ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA, USA), cDNAs corresponding to 12.5 ng of total RNA and the following PCR conditions: one cycle 501C, 2 min; 951C, 10 min; 50 cycles 601C, 1 min; 951C, 15 s. Alternative NOS1 transcripts were amplified with primers and probes complementary to the first exons 1c and 1f (forward primers) and the common exon 2 (reverse primer, probe) (for primer and probes see Saur et al.
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). As endogenous reference, the globally expressed housekeeping gene GAPDH (primers and probes were purchased from Applied Biosystems, Foster City, CA, USA) was used. For each amplicon, the amount of target and endogenous reference was determined from a standard curve generated by serial five-fold dilutions of plasmids containing the respective target sequence. The standard curve was amplified in triplicate during every experiment and the amount of target gene was normalized by the endogenous reference. Signals were analyzed by the ABI Prism Sequence Detection System software version 1.9 (Applied Biosystems, Foster City, CA, USA).
Electrophysiological and neuropsychological examinations
Forty-eight acutely psychotic inpatients of the Department of Psychiatry and Psychotherapy, University of Wü rzburg, were investigated. In these patients, VNTR1, SNP1, SNP3 and SNP4 were genotyped as described above (33 patients were also included in the single SNP association and haplotype analysis). For each of the polymorphisms, the different subgroups of patients were matched regarding their mean age, gender and handedness distribution, daily chlorpromazine equivalents of antipsychotic medication, ICD-10 diagnosis, duration of the disease, as well as number and duration of psychiatric hospitalizations in the past. There were no significant differences between the various groups of patients concerning any of the above-mentioned parameters (all t-values < 1.55, P > 0.13; all w 2 < 4.7, P > 0.3). All these patients suffered from SCZ spectrum disorders according to ICD-10 criteria (12 paranoid type; six hebephrenic type; three catatonic type; seven undifferentiated type of SCZ; 16 acute polymorphic psychotic disorders or schizophreniform disorders; five schizoaffective disorder). Eight patients had a positive family history for SCZ with an affected first-degree relative, whereas another 20 patients had first-degree relatives with non-psychotic or unknown psychiatric conditions. Neuroleptic treatment consisted of 4787385 mg (mean7s.d.) chlorpromazine equivalents per day. Each patient underwent an extensive psychopathological examination, consisting of the SCID-I-Interview, the BPRS, the Positive and Negative Symptoms Scale (PANSS), and the Hamilton Depression Rating Scale/24 Items (HDRS). Neuropsychological assessment consisted of the Verbal Fluency Test (VFT; letters and categories version), the Stroop Color Word Task, and the Trail Making Test (TMT; parts A and B).
Shortly after admittance, the patients were investigated electrophysiologically by means of a Continuous Performance Test (CPT) as published previously (e.g. Reif et al.
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). Briefly, 400 letters were presented sequentially in a pseudo-randomized order; patients were instructed to press a response button whenever the primer condition 'O' (114 stimuli) was directly followed by an 'X' (Go condition, n = 57). Nogo was defined as 'O' followed by any other letter than 'X'. Each letter was presented for 200 ms with an interstimulus interval of 1650 ms. Parallel to this task, EEG was recorded from 21 scalp electrodes. Data analysis was performed offline with the program 'Vision Analyzer' (Brain Products, Munich, Germany). The data were segmented into the different conditions of the CPT, and Go and Nogo epochs were further analyzed. Segments were averaged to one Go and one Nogo event-related potential (ERP) per subject, whereby only trials with correct responses were included in the ERP analysis. For the topographical analysis, the global field power (GFP) 60 peaks were determined within a P300 time frame (275-530 ms). At individual GFP peaks, amplitude, latency and anterior-posterior location of the positive centroid were calculated. From these data, the Nogo-anteriorization (NGA), [61] [62] [63] defined as the distance between the individual Go and Nogo centroid, was determined. Furthermore, amplitudes and latencies as traditional measures of the P300 component were analyzed at electrode positions Fz, Cz and Pz.
For the topographical ERP analysis, 2 Â 2 analyses of variance (ANOVAs) for repeated measurements were conducted for each of the four polymorphisms, with the within-subject factor 'condition' (Go versus Nogo) and the between-subject factor 'group'. For the traditional waveform ERP analysis, similar ANOVAs were calculated for the amplitudes and latencies of the P300 peaks, with the within-subjects factors 'condition' (Go versus Nogo) and 'electrode position' (Fz, Cz, Pz) and the between-subject factor 'group'. Post hoc analyses were conducted by means of two-tailed t-tests for matched or independent samples. T-tests were also used to compare the psychopathological and neuropsychological data as well as the behavioral performance during the CPT between the different groups of patients, when two genotypes were compared (e.g. SNP1 A/A and A/G versus G/G). When more than two genotypes were contrasted (e.g. VNTR1 SS, LS and LL), univariate ANOVAs were applied, followed by post hoc t-tests if indicated.
Results
Genomic control
Four highly polymorphic markers as well as the NOS1 VNTR1 itself were used to evaluate whether the patient and the control sample are genetically homogenous or not. Using the CHECKHET program, one subject has been identified carrying an abnormal genotype. Three software packages (GENEPOP, POWERMARKER and STRUCTURE) were used to investigate for population stratification both between as well as within the patient and the control sample. All calculations yielded negative results, that is, the tested samples are genetically homogenous. Using the CLUMP software, neither marker was found to be associated with the phenotype 'patient' further supporting the assumption of genetic homogeneity.
Allele and genotype frequencies Four SNPs and one VNTR of the NOS1 locus were determined and tested for association with disease, in the first step of the study by means of a single-marker association analysis. Several new alleles of VNTR1 were identified. VNTR1 alleles were distributed in a bimodal fashion (Figure 2) , with one peak for long and two peaks for short alleles. Only eight out of the 15 VNTR1 alleles observed in the present sample had a frequency greater than 1% and accounted for about 98% of the total variation (C, 17.4%; D, 5.4%; H, 18.7%; I, 2.4%; L, 13.5%; M, 7.9%; N, 30.7; O, 1.8%). This may suggest functional relevance of and/or evolutionary pressure on this polymorphism, and thus VNTR1 alleles were dichotomized in short (B-J) and long (K-R) alleles in subsequent single association studies. Of the 49 VNTR1 genotypes observed in the present sample, 21 had a frequency greater than 1% and accounted for 89% of the variation (the four most frequent genotypes were: CN, 11.6%; HN, 11.5%; NN, 9.1% and LN, 8.9%).
The frequency of SNP1 A-allele was 10.5%. As there were only five subjects with the A/A genotype (0.9%), they were grouped together with the A/G genotype (19.1%) and compared to the G/G genotype (80.0%) in subsequent single-marker association analyses. The allele and genotype frequencies of the three other SNPs, all consisting of C/T transitions, were comparable (alleles: C, B70%; T, B30%; genotypes: C/C, B49%; C/T: B42%; T/T: B9%). The genotypes of all four SNPs and VNTR1 were in Hardy-Weinberg equilibrium (P = 0.135). Table 1 gives the pairwise LD between the five NOS1 polymorphisms examined. Except for the SNP1-SNP3, and SNP1-SNP4 pairs, respectively, the polymorphisms were in significant LD. The comparably small D 0 values are presumably due to the high number of VNTR1 alleles, to the low frequency of the rare SNP1 A allele, and to the fact that the NOS1 region examined spans about 240 kilobases. Table 2 summarizes the results of the single association analyses with regard to the two presumably functional NOS1 promoter polymorphisms. w 2 tests showed that schizophrenic patients did not differ significantly from controls in dichotomized VNTR1 genotype frequencies (w 2 = 2.08, df = 2, P = 0.335), whereas the SNP1 A/A and A/G genotypes were significantly more frequent among schizophrenic patients than among controls (w 2 = 5.42, df = 1, P = 0.020). Subsequent analyses for subgroups of schizophrenic patients divided into group A and B SCZ (see Materials and methods), revealed that the association between SNP1 and SCZ was mainly due to considerably higher frequencies of the A/A and A/ G genotypes in the group B SCZ subgroup (w 2 = 8.42, df = 1, P = 0.004), whereas there was no significant effect in the group A SCZ subgroup (w 2 = 2.03, df = 1, P = 0.154). There was no significant effect of VNTR1 with regard to the two SCZ subgroups. Similarly, neither VNTR1 nor SNP1 were significantly associated with BPD (although the difference in VNTR1 LL genotype frequencies between controls and BPD actually reached marginal significance when grouping together the SS and LS genotypes and comparing them to LL; w 2 = 3.54, df = 1, P = 0.060). No significant association with SCZ or BPD were observed for all three synonymous coding SNPs (w 2 tests, df = 2, all P > 0.5; data not shown). When applying a Bonferroni correction considering all NOS1 variants and all four groups examined (i.e., SCZ total, group A SCZ, group B SCZ, and BPD), the association between SNP1 and group B SCZ (which exactly had a significance of P = 0.0037) failed to reach significance, the adjusted level of significance of a 0 = 0.05/(5 polymorphisms Â 4 patient groups) = 0.0025. It has to be noted, however, that Bonferroni correction might be too conservative for the current setting because Bonferroni correction assumes independence of the statistical tests performed, which is certainly not the case in our analyses.
Haplotype analyses
Haplotype analyses focused on the two putatively functional NOS1 promoter polymorphisms. Twentyfour VNTR1-SNP1 haplotypes were observed in the present sample. A test for global haplotype association with SCZ did not yield a significant result (P = 0.149). However, when performing haplotype association tests for SCZ subgroups as performed in the single SNP association analyses, a significant global haplotype association was found for group B SCZ (P = 0.020), whereas for group A SCZ, there was no association (P = 0.347). Table 3 shows the haplotype frequency estimates for controls and for schizophrenic patients (total sample, group A and B SCZ). There were several frequency differences between patients and controls being significant at the 5% level, but in most cases these differences were found for very rare haplotypes. One significant frequency difference, however, was observed for a more common haplotype: the estimated VNTR1(N)-SNP1(A) haplotype was present in 3.8% of the controls, but in 7.9% of patients with SCZ and even in 14.6% of the patients with group B SCZ (P = 0.002). A haplotype analysis for BPD did not yield significant results (global P = 0.533).
Mutational analysis
In 205 patients (160, SCZ; 45, bipolar affective disorder), exons critical for the catalytic function of NOS-I (2,5,6,13,14, and 27) were screened for mutations by means of dHPLC to investigate for further variants in coding regions, which could be in LD with the examined polymorphisms. The remaining exons likewise were analyzed in 20 selected patients (16, SCZ; four, bipolar affective disorder). Table 4 provides an overview on all detected mutations; variants were more frequent in the reductase domain, while the oxygenase region was highly conserved. No nonsynonymous mutations in the coding region were found.
Neuropsychological investigations
Forty-eight schizophrenic patients were investigated for an association of both neuropsychological and Global P = 0.136 Global P = 0.020 Global P = 0.347
Notes: For reasons of simplicity, only those of the 24 observed haplotypes with a frequency of at least 1% in one of the groups are shown (complete data available upon request); in parentheses: permutation-based significance of frequency differences compared to controls (10,000 permutations); bold-faced: P < 0.05; italics: meaningful frequency differences.
electrophysiological measures with VNTR1 (dichotomized in short and long alleles), SNP1 (A/A and A/G combined versus G/G), SNP3 and SNP4 genotype. With respect to psychopathological scales, carriers of SNP1 A-allele (A/A or A/G, n = 11) did not significantly differ from G/G-patients (n = 31), whereas VNTR1 genotype (SS, n = 11 patients; LS, n = 20; LL, n = 16) had a statistically significant influence on PANSS positive, HDRS and GAF scores (F2,42 = 3.87, 3.82 and 3.49, respectively; P < 0.05). Post hoc tests indicate that patients with an SS-genotype had higher values for the PANSS positive scale (t 23 = 3.14, P < 0.01) and the HDRS (t 23 = 2.56, P < 0.05) in comparison to LL-carriers (Table 5 ), which was mirrored by an accordingly low GAF score (t 23 = 2.62, P < 0.05). Compared to the heterozygous genotype (LS), the SSgroup still had significantly lower GAF-scores (t 29 = 2.24, P < 0.05). However, due to the relatively low number of SS-carriers these findings should be interpreted cautiously. With most of the other psychopathological test scores lying in-between the two homozygous genotypes, the LS-group did not differ significantly from either of them on any other scale (cf. Table 5 ).
Regarding the neuropsychological tests (VFT, Stroop Test, TMT), there was no difference in the performance of SNP1 A-allele carriers and G/G patients (Table 5) . With respect to VNTR1, a respective ANOVA indicated a trend for a statistical influence of the genotype on VFT performance (F 2,42 = 2.64, P < 0.1), with LS patients tending to perform better than SS patients (t 29 = 1.97, P < 0.1) and LL (t 32 = 1.84, P < 0.1) in the category version of the task. Reaction times and error rates in the CPT are also displayed in Table 5 . Commission errors occurred whenever a patient responded to a non-target stimulus, whereas omission errors consisted of Go conditions the patient did not respond to. While there were no significant differences between the VNTR groups for any of the behavioral measures, carriers of the SNP1 G/G-allele made significantly more omission errors than carriers of the A-allele, (t 38 = 2.07, P < 0.05), arguing for reduced attention in those patients. With respect to SNP3 and SNP4, there were neither differences in psychopathological or neuropsychological measures, nor in CPT performance (not shown). Please note that no correction for multiple testing was applied for the analysis of psychopathological and neuropsychological scores. Therefore, the results have to be considered preliminary, until larger patient samples are available that allow more conservative statistical analyses.
NGA and ERP data
Regarding the topographical ERP analysis, ANOVAs revealed significant main effects of the factor 'condition' for each of the four SNPs (all F-values > 10, P < 0.01), with no significant influence of any of the genetic subgroups. The centroids of the positive brain electrical field were always located more anteriorly in CPT Nogo-trials as compared to the Go-condition, which is a common topographical pattern ('Nogo anteriorization') similarly observed in healthy subjects. Accordingly, the NGA-values did not differ between any of the genetic subgroups (all t-values < 1, P > 0.3).
With respect to P300 latencies, the analysis of VNTR1 revealed a significant main effect of the factor 'genotype' (F 2,42 = 4.73, P < 0.05) due to overall shorter latencies for the heterozygous genotype (LS). This group of patients exhibited almost consistently shorter P300 latencies than the two homozygous genotypes, particularly in the Go condition of the CPT and particularly compared to patients with two long alleles of the NOS1 promoter (Table 6) . Regarding SNP1, an ANOVA for the P300 latencies revealed significant main effects of the factors 'electrode position' (F 2,80 = 6.81, P < 0.01) and 'genotype' (F 1,40 = 8.87, P < 0.01), as well as a significant interaction between these two factors (F 2,80 = 10.64, P < 0.001): patients with a G/G-genotype had overall longer latencies than A/A and A/G patients, which reached the level of significance for electrode site Pz in Go trials (t 40 = 2.62, P < 0.05) and for electrode positions Cz and Pz, as well as the GFP, in Nogo trials (t = 2.11, 4.15 and 2.02, respectively; P < 0.05, 0.001 and 0.05, respectively). Averaged across genotype subgroups, latencies were generally longest at electrode position Fz, shorter at Cz and shortest at Pz. The significant genotype Â electrode position interaction resulted from the fact that this pattern was reversed (Go trials) or not statistically present (Nogo trials) in the group of G/G patients.
The analysis of the P300 amplitudes revealed a significant main effect 'electrode position' (F 2,84 = 41.67, P < 0.001), as well as significant interactions 'CPT condition Â electrode position' (F 2,84 = 44.68, P < 0.001) and 'genotype group Â CPT condition' (F 2,42 = 3.84, P < 0.05) for the analysis of the VNTR1 polymorphism. The influence of the factor 'genotype' on P300 amplitudes resulted from the fact that only in the heterozygous genotype group amplitudes tended to be higher in Nogo as compared to Go trials, which can be considered as the 'normal' finding. In a direct comparison of the different genotype subgroups only one significant difference occurred, with the LS group exhibiting significantly higher Nogo amplitudes at Cz than the SS group (t 29 = 2.33, P < 0.05) ( Table 6 ).
The same analysis of the P300 amplitudes for SNP1 genotype subgroups revealed a significant main effect 'position' (F 2,80 = 34.08, P < 0.001) as well as a significant interaction 'position Â condition' (F 2,80 = 37.47, P < 0.001), with no other significant results and in particular no significant influence of SNP1 genotype on P300 amplitudes. Again, there Between-group differences were analyzed by means of two-tailed t-tests for independent samples (SNP1) and univariate ANOVAs followed by post hoc t-tests (VNTR1), respectively. Values that differed significantly between genotype subgroups were printed in bold type. For the ANOVA analysis, F-values were given and significant results were indicated (*P < 0.05; w P < 0.1). PANSS, Positive and Negative Symptom Scale; BPRS, Brief Psychiatric Rating Scale; HDRS, Hamilton depression rating scale; GAF, global assessment of functioning; VFT, verbal fluency test; TMT (B), trail making test part B; RT, reaction time; Com, commission errors; Om, omission errors.
were no significant differences between different SNP3-or SNP4-allele carriers for any of the electrophysiological variables (data not shown).
Expression of the alternative NOS1 exon 1c and 1f in the human brain As the exon 1c (G-84A; SNP1) and the exon 1f (VNTR1) promoter polymorphisms were associated with psychosis as well as prefrontal functioning, we were interested whether these alternative first exons are expressed in brain regions suggested to be involved in SCZ (frontal cortex, caudate nucleus, putamen, hippocampus). To do so, cDNA from two control brains was prepared as described. Expression of the alternative exon 1c and 1f was found in every brain region examined, with relatively high expression levels of exon 1c in the putamen and the hippocampus, whereas exon 1f was preferentially expressed in the basal ganglia ( Figure 3) . Thus, the expressional regulation exerted by SNP1 55 is active in brain regions critically involved in the etiopathogenesis of SCZ, and also the presumably functional exon 1f promoter polymorphism is operational in crucial brain regions. 
Discussion
Association of NOS1 with SCZ A large proportion of SCZ association studies were not replicated in subsequent studies. This may have been due to a range of problems: ethnic stratification, broad phenotype definition (thus, we chose to restrict the SCZ phenotype in our study to severely ill, nonremitting cases) or restriction to one, often nonfunctional SNP. By using five highly polymorphic STR markers, we undertook basic genomic control to avoid stratification artefacts, and indeed our sample proved to be genetically homogenous. One of our candidate polymorphisms, VNTR1, was included in the genomic control and found not to differ in its distribution between patients and controls. This seems counterintuitive at first sight; however, testing for genomic stratification uses single alleles, whereas for association with disease and neuropsychological as well as psychophysiological data, the 15 VNTR1 alleles were dichotomized, reflecting a presumed regulatory role of this polymorphism. Thus, functionality rather than allelic frequency likely accounts for the association of NOS1 VNTR1 with psychological and physiological parameters. That the VNTR1 has been predicted to be functional by localization 54 and that the VNTR1-containing region was demonstrated to influence gene expression 64 further supports this view. Of related interest is the fact that VNTR1 was not directly linked to disease, yet SNP1 -a promoter polymorphism with demonstrated functional significance, that is, 30% decrease in NOS1 exon 1c expression levels 55 -was significantly associated with SCZ, even more so, when the phenotype was restricted to less heritable disorders with stable residual states (type B SCZ). As VNTR1 and SNP1 regulate transcription of different alternative exons, 65 which have both previously 66 and in the present study been shown to be expressed in the human brain, and as those polymorphism are in LD, this is not contradictory but in fact strengthens the notion that NOS-I plays a role both in brain function and dysfunction as suggested by neuropsychological and psychophysiological investigation (see below). Not surprisingly, synonymous SNPs that were in LD with VNTR1 and, in the case of SNP3, also with SNP1 were neither associated with disease nor with dimensional parameters, thus explaining the contradictory findings from previous studies investigating exclusively a synonymous exon 29 and non-coding intron 29 SNP.
40-43
The 12q24 'hot spot' locus Consideration of results from pertinent linkage and association studies leads to the impression that the 12q24 locus is rather broad with no prominent single linkage peak (Figure 1 ). This points to the presence of several risk genes in this region, with relatively modest influence of individual genes. NOS1 may belong to this group of genes; DAAO (located also on 12q24), which has been linked to BPD 4 as well as SCZ, 67, 68 could be another. It will be interesting to test whether these two genes act independently or whether they are in LD with each other, probably causing false-positive association findings. Furthermore, there are several other outstanding candidate genes at the 12q24 locus, in part presently investigated in our laboratory.
Role of NOS-I in SCZ and brain function NOS-I is involved in several signaling cascades apparently involved in the pathogenesis of SCZ. First, it acts as the second messenger of the glutamatergic NMDA receptor. As hypo-functionality of the glutamate system has consistently been suggested to be implicated in SCZ, impaired NOS-I function may well contribute to a dysregulated glutamate system present in psychoses. This notion fits current conceptual frameworks on SCZ candidate genes, which all can be placed more or less convincingly in the glutamate network. 69 Furthermore, as the adaptor protein of NOS-I to the NMDA receptor CAPON has been shown to be associated with SCZ in two independent linkage analyses, 44, 45 and as there are reports showing association of NMDA receptor subunits with the disease, a genetic basis for disturbed glutamate-NO messaging gains further support. It would be a worthwhile task to investigate for epistatic interactions, once functional SNPs of other genes of the glutamatergic pathway are available.
Yet NOS-I is not only a part of the glutamatergic system, but also influences the serotonergic and dopaminergic tone in the brain by modulating monoamine transporter function. Here NO does not act by its specific receptor protein soluble G-cyclase, but by direct chemical modification of protein residues, that is, nitrosylation. By this mechanism, NO has been shown to inhibit monoamine transporters -that is, serotonin transporter (5HTT), DAT and NET -resulting in increased synaptic availability of monoamine neurotransmitters. 70 However, there are conflicting data on direct NO effects on monoamine transporters: Kilic et al. 71 demonstrated that the NO donor compound SNAP increased 5HTT function and that a mutation of the transporter, cosegregating in a large pedigree with broad phenotype serotonin-spectrum disorder, 72 results in a constitutively activated transporter. This indicates that impaired NO functioning might as well cause disturbance of serotonergic signaling. This notion is further supported by the finding that NOS-I knockout mice feature marked changes in serotonergic function: 5HT turnover is impaired, 5HT receptors are desensitized, and 5HTT expression in the brain stem neurons is decreased. 73 Regarding dopaminergic signaling, it has been shown that NO regulates striatal output by modulating the firing pattern of striatal neurons. 74 Taken together, NO appears to be a link between glutamatergic transmission on the one hand and monoaminergic system on the other, thus being centered in key pathways previously shown to be involved in the pathophysiology of SCZ.
The impact on the genetic disposition for SCZ conveyed by NOS1 variation does not reflect a major gene effect. This is, however, not expected for any common, functional polymorphism but rather for rare and potentially deleterious mutations. The fact that we detected a low degree of genetic variation of NOS1 structure highlights the importance of integrity of NO signaling. Genetic variation of NOS-I functioning therefore seems to increase the risk to develop psychosis in a non-specific mode, probably in concert with other genes and/or environmental factors. The present finding that the NOS1 VNTR1 polymorphism is not only associated with psychosis, but also influences disease severity with regards to several psychopathological measures -with VNTR1 SS carriers being more severely affected -supports this notion.
How might NOS-I contribute to the pathogenesis of SCZ at a functional level? Clues pertaining to answer this question might be derived from electrophysiological examinations, as NOS1 polymorphisms impacted significantly on P300 latency as well as amplitude. The CPT, applied in the present study, is regarded as a neuropsychological measure of sustained attention and thought to mirror prefrontal brain functioning. Especially CPT errors are attributed to anterior cingular gyrus dysfunctioning. 75 Regarding the NOS1 exon 1c promoter SNP1, the at-risk allele (À84A) interestingly was associated with less omission errors in the CPT, and with reduced P300 latencies in the both the Go and the Nogo condition. Fewer omission errors in this group of patients indicate that these subjects were more effectively focused on the task at hand, whereas the overall shorter latencies suggest an increased information processing speed. The A-allele of SNP1 thus impacts positively on both pace and accuracy of cognitive processing. SNP1 is preferentially expressed in the frontal cortex, the putamen and the hippocampus ( Figure 3) ; presence of the A-allele reduces the transcriptional efficiency of NOS1 exon 1c by approximately 30%. 55 Thus, less nitrinergic neurotransmission can be assumed in the above brain regions in carriers of the A-allele. This might be especially important in (pre-)frontal cortical areas, where almost no exon 1f expression can be found. Here, lower NO levels will result in less activation of neighboring neurons by a 'NO cloud', 70 thereby probably improving neuronal signal/noise ratio, which might provide an explanation for better attention in A-allele carriers. However, in the hippocampus, where NO functions as the second messenger of the NMDA receptor, decreased NOS-I expression might contribute to hypoglutamatergic states found in schizophrenic disorders and thus further increase susceptibility towards disease. This discrepancy in NOS-I functioning might provide a rationale for the finding that NOS1 exon 1c À84A enhances information processing, yet contributes to the genetic risk of SCZ. Likewise, an SNP in the COMT gene (Val158), which has repeatedly been associated with SCZ, has at least some beneficial effect in that it results in increased cognitive flexibility. 76 The identification of genes increasing the disposition toward disease, yet also improving cognitive domains, could aid to explain why SCZ, being a severe mental disorder, persists in the population at a global 1% lifetime prevalence.
With regards to VNTR1, the situation tends to be more complicated, as this polymorphism affected P300 amplitude as well as latency, yet neuropsychological function by and large remained unaffected. Heterozygous subjects had significantly shortened P300 latencies for conditions involving response execution (Go), which indicates an increased information processing speed particularly during conditions that demand the execution of a prepared motor response. At the same time, they showed increased ERP amplitudes during response inhibition (Nogo) over central scalp areas. This finding indicates an enhanced cerebral activation within frontally located structures that were suggested to be involved in inhibitory control. 77, 78 The overall pattern of the amplitude data (larger P300 amplitudes in Nogo as compared to Go trials) was also closest to 'normal' in this group of patients, which once again underlines a positive influence of the heterozygous genotype on basic mechanisms of response inhibition and cognitive response control. These findings are in line with the concept of positive 'molecular heterosis', that refers to situations in which subjects heterozygous for a genetic polymorphism show a stronger effect for a quantitative (phenotypic) trait than subjects homozygous for either allele (for a review on the subject see Comings and MacMurray 79 ). Interestingly, the SS genotype was associated with significantly decreased P300 Nogo amplitudes (Table 6 ). This might indicate that both polymorphisms modulate the recruitment of neuronal assemblies suppressing already initiated motor responses. By ineffectively doing so, the atrisk alleles thus might contribute to defective response control found in schizophrenic disorders. The differing functional impact of both NOS1 polymorphisms can readily be explained by the fact that both promoter variants code for distinct alternative first exons, expressed in different spatial patterns (Figure 3 ).
In conclusion, the key findings of the present study are: (1) a functional SNP in the promoter region of NOS1 is associated with SCZ, and is related to worse (pre-)frontal brain functioning, (2) a presumably functional promoter VNTR of NOS1 results in more severe psychopathology and influences response control, and (3) an NOS1 minihaplotype is associated with SCZ. Collectively, three separate lines of evidence thus suggest that NOS1 genotype is associated with SCZ and affects brain functioning. Further research on the role of these NOS1 variations in disease and normal brain functioning are warranted, as NOS-I provides a novel and innovative target in the treatment of mental disorder.
Abbreviations
5HTT, serotonin transporter; BPD, bipolar affective disorder; BPRS, Brief Psychiatric Rating Scale; CPT, continuous performance test; dHPLC, denaturing high-performance liquid chromatography; ERP, event-related potentials; GAF, global assessment of functioning; GFP, global field power; HDRS, Hamilton Depression Rating Scale/24 Items; LD, linkage disequilibrium; MD, major depression; NGA, Nogoanteriorization; NMDA, N-methyl-D-aspartate; NOS, nitric oxide synthase; PANSS, Positive and Negative Symptoms Scale; SCZ, schizophrenia; SNP, single nucleotide polymorphism; STR, short tandem repeat; TMT, trail making test; VFT, verbal fluency test; VNTR, variable number of tandem repeats.
